BIAL Biotech to be based in Cambridge, Massachusetts and will be a ResearchCenter of Excellence dedicated to genetically-defined Parkinson’s disease• LTI-291 clinical program and other… Read More
WATERTOWN, Mass., Aug. 20, 2020 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a… Read More
Phase 1/2 “INTREPID” trial to evaluate safety and ability of engineered FGF-1 to regenerate corneal endothelial cells August 19, 2020 07:00 AM Eastern Daylight… Read More
Therapy currently being evaluated in Phase I/II clinical study Company formed with $8.15 million Series 1; led by founding investors Hatteras Venture Partners and the… Read More
– Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments – – Kymera to retain option during clinical development… Read More
Financing will advance two ARC™ clinical programs and expand pipeline development — DURHAM, NC and AUSTIN, TX – June 15, 2020 – Shattuck… Read More
PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) “VANGARD” trial will assess the efficacy and safety of PB1046… Read More
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. announced today that is has completed a $25M Series B financing. The… Read More
CAMBRIDGE, Mass., March 12, 2020 /PRNewswire/ — Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today… Read More
NASHVILLE, Tenn.–(BUSINESS WIRE)–HealthStream (Nasdaq: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, today announced that it has acquired… Read More